Format

Send to

Choose Destination
J Am Coll Cardiol. 2018 Jan 2;71(1):25-36. doi: 10.1016/j.jacc.2017.10.062. Epub 2017 Nov 1.

Beating-Heart Mitral Valve Repair Using a Novel ePTFE Cordal Implantation Device: A Prospective Trial.

Author information

1
Division of Cardiac Surgery, University of Maryland School of Medicine, Baltimore, Maryland. Electronic address: Jsgammiemd@gmail.com.
2
Jagiellonian University John Paul II Hospital, Krakow Poland.
3
Brigham and Women's Hospital, Boston, Massachusetts.
4
Institute of Cardiology, Warsaw, Poland.
5
Royal Brompton and Harefield National Health Service Foundation Trust, London, United Kingdom.
6
University Hospital Southampton National Health Service Foundation Trust, United Kingdom.
7
Padova University Hospital, Padova, Italy.
8
Ospedale San Raffaele, Milan, Italy.
9
Massachusetts General Hospital, Boston, Massachusetts.

Abstract

BACKGROUND:

Conventional mitral valve (MV) operations allow direct anatomic assessment and repair on an arrested heart, but require cardiopulmonary bypass, aortic cross-clamping, sternotomy or thoracotomy, and cardioplegic cardiac arrest, and are associated with significant perioperative disability, and risks of morbidity and mortality.

OBJECTIVES:

This study evaluated safety and performance of a transesophageal echocardiographic-guided device designed to implant artificial expanded polytetrafluoroethylene (ePTFE) cords on mitral leaflets in the beating heart.

METHODS:

In a prospective multicenter study, 30 consecutive patients with severe degenerative mitral regurgitation (MR) were treated with a mitral valve repair system (MVRS) via small left thoracotomy. The primary (30-day) endpoint was successful implantation of cords with MR reduction to moderate or less.

RESULTS:

The primary endpoint was met in 27 of 30 patients (90%). Three patients required conversion to open mitral surgery. There were no deaths, strokes, or permanent pacemaker implantations. At 1 month, MR was mild or less in 89% (24 of 27) and was moderate in 11% (3 of 27). At 6 months, MR was mild or less in 85 % (22 of 26), moderate in 8% (2 of 26), and severe in 8% (2 of 26). Favorable cardiac remodeling at 6 months included decreases in end-diastolic (161 ± 36 ml to 122 ± 30 ml; p < 0.001) and left atrial volumes (106 ± 36 ml to 69 ± 24 ml; p < 0.001). The anterior-posterior mitral annular dimension decreased from 34.7 ± 5.8 mm to 28.2 ± 5.1 mm; p < 0.001 as did the mitral annular area (10.0 ± 2.7 cm2 vs. 6.9 ± 2.0 cm2; p < 0.0001).

CONCLUSIONS:

MVRS ePTFE cordal implantation can reduce the invasiveness and morbidity of conventional MV surgery. The device's safety profile is promising and prospective trials comparing the outcomes of the MVRS to conventional MV repair surgery are warranted. (CE Mark Study for the Harpoon Medical Device [TRACER]; NCT02768870).

KEYWORDS:

echocardiography; mitral valve; regurgitation; surgery; valvuloplasty

PMID:
29102688
DOI:
10.1016/j.jacc.2017.10.062
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center